Compare Hyatt Hotels Corporation (H) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs 10X Genomics Inc — how do they compare? Hyatt Hotels Corporation trades at $172.22 (market cap $16.03B), while 10X Genomics Inc trades at $58.6 (market cap $7.64B). The key difference: Hyatt Hotels Corporation is far larger — about 2.1× 10X Genomics Inc's market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| H | TXG | |
|---|---|---|
Market Cap | $16.03B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $58.57 |
52-Week Low | $135.42 | $11.34 |
Enterprise Value | $19.93B | $7.17B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corp (H) trades at $177.71, down 0.65% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings beats in Q2 2026 and a raised RevPAR outlook highlight operational momentum, but high valuation ratios and a negative net income in 2025 pose concerns. The stock is near its 52-week high of $206.86, with support at $176 and resistance at $180.
The outlook is cautious; while fee growth and travel demand support expansion, the stock's rich valuation and debt levels warrant patience. Risks include regional weakness and project delays. Analysts maintain a mixed consensus with a $201 price target, suggesting limited near-term upside amid balanced investor sentiment.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
